Ljubljana, October 26 – Lek has donated a defibrillator to Radio Slovenia, which will be available for the staff of the radio station to use, but it is also intended for public use. This donation is a contribution to the campaign by radio station VAL 202 called “Seconds Can Save You.” The staff of VAL 202 have used this campaign to inform the highest possible number of people about the importance of assisting those who suffer heart attacks by using resuscitation and defibrillators to help them survive until the arrival of medical personnel.
The defibrillator, which is intended to be used by radio staff and the general public, will be part of the network of publicly accessible defibrillators, and you can already find out from the Ljubljana Dispatching Center that there is a publicly accessible defibrillator in the entrance hall of Radio Slovenia at Tavčarjeva 17 in Ljubljana.
At the final event of the Seconds Can Save You campaign on Wednesday, October 24, Head Marketing and Sales Slovenia Katja Razinger presented the automatic defibrillator to the editor-in-chief of VAL 202 Mirko Štular. The radio staff installed it in the entrance hall, and a representative of the mobile rescue unit demonstrated how to use the apparatus to the assembled guests and representatives of the media.
In their campaign from September 24 to 29, the radio staff encouraged people all over Slovenia to participate in free resuscitation courses. 30 defibrillators were donated during the campaign, and Lek decided to donate a defibrillator which according to the representative of the mobile rescue unit is compatible with the equipment used by the rescue service, which is very important.
At Lek we also have two defibrillators, and we recognized the need for publicly accessible defibrillators in 2005. Therefore we contributed funds for the purchase of two defibrillators: one is located in the Maximarket underpass, and the other is a mobile unit which travels around Slovenia.
Lek, a Sandoz company, is one of the pillars of leading world generics company Sandoz. It operates as a global development center for products and technologies, as a global manufacturing center for active pharmaceutical ingredients and medicines, as a competence center for the development of vertically integrated products, as a Sandoz competence center in the field of development and manufacturing of biopharmaceutical products and as a supply center for the markets of CEE, SEE and CIS, sales Slovenia and sales services for Sandoz’s global markets. Lek d.d. employs about 2,820 people and achieved total sales of USD 904 million in 2006. For further information please consult http://www.lek.si
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 840 active substances in over 5 000 forms worldwide. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these drugs along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to the strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and EonLabs (U.S.) and sells its products in more than 110 countries. In 2006, Sandoz employed around 21,000 people worldwide and posted sales of USD 6 billion.
Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics and leading self-medication OTC brands. In 2006, the Group’s businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For further information contact:
Katarina Klemenc Dinjaški
Lek Pharmaceuticals d.d.
Phone: + 386 1 580 22 43
Fax: + 386 1 580 24 32